Travere Therapeutics (TVTX)
(Delayed Data from NSDQ)
$7.42 USD
+0.40 (5.70%)
Updated May 31, 2024 04:00 PM ET
After-Market: $7.42 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
Travere Therapeutics, Inc. [TVTX]
Reports for Purchase
Showing records 61 - 80 ( 130 total )
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Upgrading to Outperform: Seeing A Glass Half Full, With Filspari Current Label
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
FILSPARI Approved but Label More Cautious Than Expected; Multiple Near-Term Catalysts Remain; Raise PT to $40
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Filspari (sparsentan) Enters The IgAN Era With FDA Approval
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Thoughts Ahead of Tomorrow''s PDUFA for Sparsentan in IgAN; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
HCW 2023 Top Picks: Seize the Opportunities
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology Survey Says: Nephrology Survey Checks Pulse On IgAN Market
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology- 4Q22 Commercial Biotech Preview: A New Hope
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Travere Outlines 2023 Milestones; Sparsentan IgAN PDUFA on February 17 Is a Major Catalyst; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provides 4Q22 Preannouncement, Outlines FY23 Goals With Sparsentan Up First
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q Recap; Revised REMS Proposal For Sparsentan in IgAN Submitted; New PDUFA Date February 17, 2023; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
With ASN/Kidney Week Approaching, TVTX Focuses on 2/17/23 PDUFA
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Year Of The Kidney Extended To 2023 As Sparsentan PDUFA Shifts Out on REMS Add
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Sparsentan PDUFA Delayed; Reducing PT to $36 on More Gradual Uptake and Potential Liver Tox Risk
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E